How effective is Vibegron?

Vibegron, a β3 adrenergic receptor agonist, has shown promising efficacy in the treatment of overactive bladder (OAB). Clinical studies have shown that this drug can effectively relieve the symptoms of urinary urgency, frequency and urge urinary incontinence in OAB patients and improve their quality of life. Compared with traditional anticholinergic drugs, Vibegroron is less likely to cause side effects such as dry mouth and constipation, so it is better tolerated and is suitable for patients who are intolerant to other drugs.

In a pivotal Phase III clinical trial, patients treated with once-daily treatment with Vibegroron 75 mg for 12 weeks showed a significant reduction in the number of daily urinations and a significant decrease in the incidence of urinary urgency and urge incontinence. In addition, Vibegroron has a faster onset of action, and some patients can experience improvement in symptoms within a few days of taking the medication. Long-term use studies show that the drug's efficacy lasts for at least a year and is relatively safe.

Compared with similar β3 receptor agonists such as Mirabegron (Mirabegron), Verbegron has certain advantages in some aspects. For example, Verbegeron is more selective for β3 receptors and therefore has less of an effect on blood pressure. In addition, studies have found that Vibegroron may have some anti-inflammatory effects, which may provide additional benefits for some patients with OAB due to bladder inflammation.

Overall, Vibegroron is an effective, safe, and well-tolerated OAB treatment, especially in patients requiring long-term treatment. Its good efficacy and relatively few adverse effects make it an important treatment option in addition to anticholinergic drugs. However, individual responses to medications may vary, so you should consult your doctor before use and tailor your treatment to your individual circumstances.

Reference materials:https://www.gemtesa.com/